Market research
AUTL Autolus Therapeutics Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 641M
- P/E ratio
- Not available
- Analyst target
- 8.725
- Dividend yield
- Not available
- Beta
- 2.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US05280R1005
- Market cap
- 641M
- P/E ratio
- Not available
- Analyst target
- 8.725
- Dividend yield
- Not available
- Beta
- 2.0
About
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AUTL discussion.
5 years, 4 months ago
Autolus Therapeutics plc is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 6.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1259.1.
Autolus Therapeutics plc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 4.7% to $-43M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.6% to $-33M since the same quarter in the previous year.
Based on the above factors, Autolus Therapeutics plc gets an overall score of 2/5.